Answers are grounded in this paper and cite their sources.
Dalbavancin treatment for Gram-positive PJIs resulted in a similar outcome to SoC, with excellent safety and low rate of adverse effects. Dalbavancin seems to be a promising antimicrobial against PJIs by reducing the risk of Gram-positive re-infections and allowing a less frequent dosage with potential outpatient IV treatment.
No takes yet. Share an insight, caveat, or question.
Simon et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: